Lenvatinib in Combination With Pembrolizumab Versus Treatment of Physician's Choice in Participants With Advanced Endometrial Cancer (MK-3475-775/E7080-G000-309 Per Merck Standard Convention [KEYNOTE-775])
Public ClinicalTrials.gov record NCT03517449. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Pembrolizumab Versus Treatment of Physician's Choice in Participants With Advanced Endometrial Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a study of pembrolizumab (MK-3475, KEYTRUDA®) in combination with lenvatinib (E7080) versus treatment of physician's choice (doxorubicin or paclitaxel) for the treatment of advanced endometrial cancer. Participants will be randomly assigned to receive either pembrolizumab and lenvatinib or treatment of physician's choice. The primary study hypothesis is that pembrolizumab in combination with lenvatinib prolongs progression free survival (PFS) and overall survival (OS) when compared to treatment of physician's choice.
Study identification
- NCT ID
- NCT03517449
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 827 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 10, 2018
- Primary completion
- Feb 28, 2022
- Completion
- Feb 25, 2025
- Last update posted
- Mar 18, 2026
2018 – 2025
United States locations
- U.S. sites
- 25
- U.S. states
- 17
- U.S. cities
- 25
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Arizona Oncology Associates, PC- HAL | Phoenix | Arizona | 85016 | — |
| University of California San Francisco | San Francisco | California | 94158 | — |
| University of California Los Angeles | Santa Monica | California | 90095 | — |
| Smilow Cancer Hospital at Yale New Haven | New Haven | Connecticut | 06510 | — |
| University of Miami Health System | Miami | Florida | 33136 | — |
| Florida Hospital Cancer Institute | Orlando | Florida | 32804 | — |
| Georgia Cancer Center at Augusta University | Augusta | Georgia | 30912 | — |
| North Shore University Health System | Evanston | Illinois | 60201 | — |
| University Medical Center New Orleans | New Orleans | Louisiana | 70112 | — |
| Greater Baltimore Medical Center | Baltimore | Maryland | 21204 | — |
| Maryland Oncology Hematology, P.A. | Wheaton | Maryland | 20902 | — |
| John Theurer Cancer Center at Hackensack University Med Ctr | Hackensack | New Jersey | 07601 | — |
| Holy Name Medical Center | Teaneck | New Jersey | 07666 | — |
| Memorial Sloan Kettering Cancer Center | New York | New York | 10022 | — |
| University of Rochester | Rochester | New York | 14642 | — |
| Duke University Medical Center | Durham | North Carolina | 27710 | — |
| Stephenson Cancer Center | Oklahoma City | Oklahoma | 73104 | — |
| Willamette Valley Cancer Institute and Research Center | Eugene | Oregon | 97401 | — |
| Sanford Gynecology Oncology | Sioux Falls | South Dakota | 57104 | — |
| UT West Cancer Center | Germantown | Tennessee | 38138 | — |
| Texas Oncology-South Austin | Austin | Texas | 78745 | — |
| University of Texas Southwestern Medical Center at Dallas | Dallas | Texas | 75390-9032 | — |
| The University of Texas MD Anderson Cancer Center | Houston | Texas | 77030 | — |
| Texas Oncology-San Antonio Medical Center | San Antonio | Texas | 78240 | — |
| Utah Cancer Specialists | Salt Lake City | Utah | 84106 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 144 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03517449, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 18, 2026 · Synced Sep 7, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03517449 live on ClinicalTrials.gov.